tbuckley/cabot-search huggingface dataset:
Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes
Authors: Dan R. Berlowitz, Capri G. Foy, Lewis E. Kazis, Linda P. Bolin, Molly B. Conroy, Peter Fitzpatrick, Tanya R. Gure, Paul L. Kimmel, Kent Kirchner, Donald E. Morisky, Jill Newman, Christine Olney, Suzanne Oparil, Nicholas M. Pajewski, James Powell, Thomas Ramsey, Debra L. Simmons, Joni Snyder, Mark A. Supiano, Daniel E. Weiner, Jeff Whittle
Journal: New England Journal of Medicine (2017)

The previously published results of the Systolic Blood Pressure Intervention Trial showed that among participants with hypertension and an increased cardiovascular risk, but without diabetes, the rates of cardiovascular events were lower among those who were assigned to a target systolic blood pressure of less than 120 mm Hg (intensive treatment) than among those who were assigned to a target of less than 140 mm Hg (standard treatment). Whether such intensive treatment affected patient-reported outcomes was uncertain; those results from the trial are reported here.We randomly assigned 9361 participants with hypertension to a systolic blood-pressure target of less than 120 mm Hg or a target of less than 140 mm Hg. Patient-reported outcome measures included the scores on the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the Veterans RAND 12-Item Health Survey, the Patient Health Questionnaire 9-item depression scale (PHQ-9), patient-reported satisfaction with their blood-pressure care and blood-pressure medications, and adherence to blood-pressure medications. We compared the scores in the intensive-treatment group with those in the standard-treatment group among all participants and among participants stratified according to physical and cognitive function.Participants who received intensive treatment received an average of one additional antihypertensive medication, and the systolic blood pressure was 14.8 mm Hg (95% confidence interval, 14.3 to 15.4) lower in the group that received intensive treatment than in the group that received standard treatment. Mean PCS, MCS, and PHQ-9 scores were relatively stable over a median of 3 years of follow-up, with no significant differences between the two treatment groups. No significant differences between the treatment groups were noted when participants were stratified according to baseline measures of physical or cognitive function. Satisfaction with blood-pressure care was high in both treatment groups, and we found no significant difference in adherence to blood-pressure medications.Patient-reported outcomes among participants who received intensive treatment, which targeted a systolic blood pressure of less than 120 mm Hg, were similar to those among participants who received standard treatment, including among participants with decreased physical or cognitive function. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062 .).
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Authors: Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen
Journal: Journal of Clinical Oncology (2017)

Purpose To establish the safety profile and antitumor activity of the anti-programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) that expressed programmed death-ligand 1 (PD-L1). Patients and Methods KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors. Key eligibility criteria for the NPC cohort included unresectable or metastatic disease, failure on prior standard therapy, and PD-L1 expression in 1% or more of tumor cells or tumor-infiltrating lymphocytes. Patients received pembrolizumab 10 mg/kg every 2 weeks up to 2 years or until disease progression or unacceptable toxicity. Primary end point was objective response rate (ORR) per investigator review. Tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) every 8 weeks for the first 6 months and every 12 weeks thereafter. Results Twenty-seven patients received pembrolizumab. Median age was 52.0 years (range, 18 to 68 years); 92.6% received prior therapies for RM-NPC; 70.4% had received three or more therapies. Partial response and stable disease were observed in seven and 14 patients, respectively, for an ORR of 25.9% (95% CI, 11.1 to 46.3) over a median follow-up of 20 months. ORR by central review was similar (26.3%). Drug-related adverse events that occurred in 15% or more of patients included rash (25.9%), pruritus (25.9%), pain (22.2%), hypothyroidism (18.5%), and fatigue (18.5%). Grade ≥ 3 drug-related adverse events occurred in eight patients (29.6%), and there was one drug-related death (sepsis). As of the data cutoff (June 20, 2016), two patients remained on pembrolizumab treatment. Conclusion Pembrolizumab demonstrated antitumor activity and a manageable safety profile in patients with RM-NPC.
Endogenous Fungal Endophthalmitis
Authors: Nidhi Relhan, Stephen G. Schwartz, Harry W. Flynn
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation
Authors: Mona Alibolandi, Khalil Abnous, Marzieh Mohammadi, Farzin Hadizadeh, Fatemeh Sadeghi, Sahar Taghavi, Mahmoud Reza Jaafari, Mohammad Ramezani
Journal: Journal of Controlled Release (2017)
Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort
Authors: Zineb Ez-Zaitouni, Robert B M Landewé, Désirée van der Heijde, Floris A van Gaalen
Journal: Annals of the Rheumatic Diseases (2017)

We recently published a study investigating whether the mere presence of multiple spondyloarthritis (SpA) features is sufficient for an axial spondyloarthritis (axSpA) diagnosis.1 Patients (n=500) with chronic back pain (CBP) suspected of axSpA were stratified according to their number of SpA features into four subgroups: ≤1, 2, 3 and ≥4 SpA features based on medical history taking, physical examination and measurement of acute phase reactants, but before sacroiliac imaging and HLA-B27 testing. In total, 24% (38/159), 43% (62/143), 62% (49/79) and 85% (101/119) of CBP patients with ≤1, 2, 3 and ≥4 SpA features, respectively, were diagnosed with axSpA. In particular, HLA-B27 positivity and imaging findings highly suggestive of axSpA were strongly associated with an axSpA diagnosis. Although …
Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC).
Authors: Gijs Verheijden, Patrick Beusker, Ruud Ubink, Miranda van der Lee, Patrick Groothuis, Peter J. Goedings, David Egging, Ellen Mattaar, Macro Timmers, Wim Dokter
Journal: Journal of Clinical Oncology (2014)

626 Background: SYD985 is a HER2-targeting ADC based on trastuzumab and vc-seco-DUBA, Synthon Biopharmaceuticals proprietary cleavable linker-duocarmycin payload. This paper describes the direct comparison of SYD985 to T-DM1 (ado-trastuzumab emtansine) in vitro and in vivo. Methods: Cell survival was tested in 96-wells plates using the CellTiter-Glo luminescent assay kit (Promega); cell line-based and breast cancer patient-derived tumor-based xenograft experiments were done in SPF athymic nu/nu mice (n=8 per group). A polyclonal rabbit anti-human HER2 (DAKO) antibody was used in the IHC analysis. In vitro data analysis comprised the sigmoidal dose-response equation with variable slope in GraphPad Prism. Results: In vitro, SYD985 and T-DM1 were compared head-to-head in a panel of 8 cell lines expressing different levels of HER2. In cell lines with high HER2 expression (HER2 3+), both SYD985 and T-DM1 show similar potencies and activities. In cell lines with low HER2 expression (HER2 2+ and 1+), SYD985 was a factor 3- to over 50-fold more potent than T-DM1. In vivoanti-tumor activity was assessed in a series of cell line and patient-derived breast cancer xenograft studies with varying HER2 levels, including FISH-positive / IHC-HER2 3+ and FISH-negative / IHC-HER2 2+ and 1+ models. Both SYD985 and T-DM1 showed anti-tumor activity in the FISH-positive / IHC-HER2 3+ models, although SYD985 appeared to be somewhat more active. Whereas SYD985 showed very potent anti-tumor activity in the FISH-negative models that were either IHC-HER2 2+ or 1+, T-DM1 was not active, indicating superior anti-tumor activity of SYD985 over T-DM1. The data are corroborated by similar results in gastric cancer models. Conclusions: The preclinical profile of SYD985 enables extending the target population of breast and gastric cancer patients that may respond to this treatment modality to include FISH-negative / IHC-HER2 2+ and 1+ patients. Early phase clinical trials with SYD985 in breast and gastric cancer patients with this tumor profile, besides the classical FISH-positive and/or IHC-HER2 3+ indication, appear justified and warranted.
胃癌細胞におけるCD44オルタナティブスプライシングは培養次元および基質硬度により調節される【Powered by NICT】
Authors: Branco da Cunha Cristiana, D Klumpers Darinka, T Koshy Sandeep, C Weaver James, Chaudhuri Ovijit, Seruca Raquel, Carneiro Fatima, L Granja Pedro, J Mooney David
Journal: Biomaterials (2016)
Bugs, drugs, and HIV: the role of the vaginal microbiome in HIV risk and antiretroviral efficacy for HIV prevention
Authors: Lenine J. P. Liebenberg, Derseree Archary, Aida Sivro, Douglas S. Kwon
Journal: Genome Medicine (2017)

Advances in molecular tools to characterize the microbiome have led to the discovery of unique roles for microbes in human disease. Findings that the female genital microbiome can influence HIV acquisition and prevention emphasize the importance of microbiome analysis in clinical trials that assess the efficacy of HIV prevention interventions.
トリプルネガティブ乳癌のための3D micrometastasic腫瘍組織類似体における磁気ナノ粒子の遠隔操作により誘起された磁気温熱療法の毒性評価【Powered by NICT】
Authors: A Stocke Nathanael, Sethi Pallavi, Jyoti Amar, Chan Ryan, M Arnold Susanne, Hilt J. Zach., Upreti Meenakshi
Journal: Biomaterials (2017)
Does terminology from biology work in the realm of operant behaviour?
Authors: Mecca Chiesa
Journal: Behavioral and Brain Sciences (2001)

The authors note that theoretical revision is likely to be required to refine and clarify a general theory of selection so that it is capable of accounting for selection processes across different subject matters. Some aspects of conceptual language from the biological realm work across all three domains. However, terminological revision may be required where concepts of “replication” and “information” pose particular problems for the general theory as that is applied to operant research.
SP0032 The contribution of physiotherapists to early detection of inflammatory arthritis
Authors: P Kirwan
Journal: Annals of the Rheumatic Diseases (2017)

Early recognition of inflammatory arthritis is of utmost importance, as failure to do so can delay appropriate treatment and result in permanent joint damage and disability. This presentation will set out to explore the role a Physiotherapist/Healthcare Professional can play in recognition of inflammatory joint disease. Healthcare Professionals/Physiotherapists are often the first point of contact for patients suffering from joint/musculoskeletal pain. They are therefore very well positioned to be the first to identify possible inflammatory sources of pain versus non-inflammatory sources. Useful clinical tools which aid in this decision making process will be discussed. The question as to whether a physiotherapist can recognise inflammatory joint disease versus non-inflammatory joint conditions will be explored with the aim being to highlight the important role a physiotherapist can play in this important diagnostic challenge. With reference to ongoing clinical and research work in this field, this presentation will set out to ask whether or not a Healthcare Professional/Physiotherapist can accurately recognise/diagnose inflammatory arthritis and whether they miss inflammatory arthritis. <h3>Disclosure of Interest</h3> None declared
On the way to the Tokyo Summer Olympic Games (2020). Prevention of severe head and neck injuries in judo: it’s time for action
Authors: Takeshi Kamitani, Nikolaos G Malliaropoulos, Masaki Omiya, Yohei Otaka, Kosei Inoue, Natsuko Onidani
Journal: British Journal of Sports Medicine (2017)

Severe head and neck injuries resulting in death or serious sequelae in judo have been recently reported in Japan,1 2 reaffirming the importance of establishing effective measures to reduce such serious injuries. We describe how and in whom the severe head and neck injuries occur in judo and outline the potentially preventive strategies.

Judo is a whole-body sport; however, injuries of the knee, shoulder and fingers are common.3 Head and neck injuries are rarer, with incidences of 2.44 and 1.47 cases per 100 000 judokas per year, respectively, but they tend to be more serious.1 According to accident reports submitted to the All Japan Judo Federation’s System, there were 30 cases of head injury and 19 cases of neck injury reported between 2003 and 2010.1 

Young players aged <20 years accounted for 90% (27/30) of cases of head injury. Many of the victims of these injuries had <1 year of experience. Head injuries occurred while being thrown in approximately 70% (21/30) of cases during osoto-gari. Osoto-gari …
Importance of Genetic Influence on the Occurrence of Mammary Tumors in Virgin Female Mice
Authors: Walter E. Heston, Howard B. Andervont
Journal: JNCI Journal of the National Cancer Institute (1944)

Journal Article Importance of Genetic Influence on the Occurrence of Mammary Tumors in Virgin Female Mice Get access Walter E. Heston, Walter E. Heston geneticist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Howard B. Andervont Howard B. Andervont principal biologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 4, February 1944, Pages 403–407, https://doi.org/10.1093/jnci/4.4.403 Published: 01 February 1944
ヌクレオリン標的微小気泡のin vitro特性化とin vivo超音波分子イメージング【Powered by NICT】
Authors: Zhang Hua, S Ingham Elizabeth, M J Gagnon Karen, M Mahakian Lisa, Liu Jingfei, L Foiret Josquin, K Willmann Juergen, W Ferrara Katherine
Journal: Biomaterials (2017)
Idiopathic Acute Exudative Polymorphous Vitelliform Maculopathy
Authors: Irene Barbazetto, Kunal K. Dansingani, Rosa Dolz-Marco, Alfonso Giovannini, F.C. Piccolino, Anita Agarwal, Luiz H. Lima, Raul N. Vianna, Lawrence A. Yannuzzi
Journal: Ophthalmology (2017)
Cancer Mortality Among Farmers: Reply
Authors: Burmeister, Leon F.
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article Cancer Mortality Among Farmers: Reply Get access Leon F. Burmeister, Ph.D. Leon F. Burmeister, Ph.D. Department of Preventive Medicine and Environmental Health College of Medicine The University of IowaIowa City, Iowa 52242 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 72, Issue 3, March 1984, Page 504, https://doi.org/10.1093/jnci/72.3.504 Published: 01 March 1984
AB0286 14 cases study of macrophage activation syndrome (MAS) in systemic onset juvenile idiopathic arthritis
Authors: X Chen, H Zeng
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Macrophage activation syndrome (MAS) is a severe, potentially life-threatening syndrome. <h3>Objectives</h3> we aim to review the precipitating events,clinical features, treatment, and outcome of macrophage activation syndrome (MAS).Part patients were analysed the Polymorphisms of Perforin A91V (NCBI:SNP rs35947132) using special primers by polymerase chain reaction (PCR). <h3>Methods</h3> Retrospective review of cases of MAS from a prospectively collected database of children with autoimmune diseases from 2003 to 2008. <h3>Results</h3> Fourteen patients (nine boys) were considered to have evidence of MAS.The primary diagnosis was systemic onset juvenile idiopathic arthristis, with age ranged from 5 months to 12 years. No medication was identified as trigger. Eleven had infections prior to MAS,specific infectious agents were identified in four. High grade fever, new onset hepatosplenomegaly, lymphadenopathy, dysfunction of liver,abnormal fat metabolism and hemophagocytosis were common clinical features.Two cases were with ARDS and MOF in three and three died. The perforin A91V (NCBI:SNP rs35947132) gene was detected in seven systemic onset juvenile idiopathic arthritis compolicated with MAS cases, but no mutation were found. Glucocorticoid, intravenous immunoglobulin, immunoimpressive therapy were effective and HP (Plasmapheresis) used in one serious case was also effective. <h3>Conclusions</h3> MAS is a rare and potentially fatal complication of childhood rheumatoid diseases,especially systemic onset juvenile idiopathic arthritis. Most of our patients were male, and most cases were preceded by infection. Bone marrow studies support the diagnosis. MOF may be a poor prognostic sign.Aggressive early therapy is essential. <h3>Disclosure of Interest</h3> None declared
ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer.
Authors: Partha Basu, Ajay O. Mehta, Minish Mahendra Jain, Sudeep Gupta, Rajnish Vasant Nagarkar, Vijay Kumar, Sumana Premkumar, Rakesh Neve, Subhashini John, Robert G. Petit
Journal: Journal of Clinical Oncology (2014)

5610 Background: ADXS11-001 immunotherapy is a live attenuated Listeria monocytogenes (Lm) bioengineered to secrete a HPV-16-E7 fusion protein targeting HPV transformed cells. The Lm vector serves as its own adjuvant and infects APC where it cross presents, stimulating MHC class 1 and 2 pathways resulting in specific T-cell immunity to tumors. Here we describe final results from Lm-LLO-E7-015, a randomized P2 study designed to evaluate the safety and efficacy of ADXS11-001 with and without cisplatin in 110 patients with recurrent cervical cancer in India; previously treated with chemotherapy, radiotherapy or both. Methods: Patients were randomized to either 3 doses of ADXS11-001 at 1 x 109 cfu or 4 doses of ADXS11-001 at 1 x 109 cfu with cisplatin chemotherapy (40 mg/m2). Naprosyn and oral promethazine were given as premedications and a course of ampicillin was given 72h after infusion. Patients received CT scans at baseline and 3, 6, 9, 12 and 18 months. The primary endpoint was overall survival. Results: The final 12 month survival was 36% (39/110) and 18-month survival was 28% (31/110). The response rate was 11% (6 CRs and 6 PRs/110) with tumor responses observed in both treatment arms; 35 additional patients had stable disease > 3 months, for a disease control rate of 43% (47/110). Average duration of response in both treatment groups was 10.5 months. Activity against different high-risk HPV strains was observed. The incidence of SAEs possibly related or related to ADXS11-001 was 2% (G3). The majority of non-serious adverse events were predominately infusion associated, and either resolved on their own or responded to symptomatic treatment. Conclusions: The addition of cisplatin to ADXS11-001 did not significantly improve survival outcomes or tumor responses. Baseline ECOG performance status, type of prior therapy, or aggressiveness of disease had no effect on survival outcomes and tumor responses. The 36% 12 month survival, 28% 18 month survival, and 11% response rate observed in this recurrent disease setting is encouraging and suggests that ADXS11-001 is an active agent in recurrent cervical cancer. Additional sub-analyses will be presented at the meeting.
小分子低酸素癌薬の成分としてのアゾベンゼンの再考:セラノスティック事例研究【Powered by NICT】
Authors: Verwilst Peter, Han Jiyou, Lee Jiyeong, Mun Sora, Kang Hee-Gyoo, Kim Jong Seung
Journal: Biomaterials (2017)
リガンド標的蛍光プローブを用いた肝細胞癌におけるβ‐ガラクトシダーゼ誘導活性のin vivoイメージング【Powered by NICT】
Authors: Kim Eun-Joong, Kumar Rajesh, Sharma Amit, Yoon Byungkwon, Kim Hyun Min, Lee Hyunseung, Hong Kwan Soo, Kim Jong Seung
Journal: Biomaterials (2017)
High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
Authors: J R Mills, D R Barnidge, A Dispenzieri, D L Murray
Journal: Blood Cancer Journal (2017)

We assessed the ability of a mass spectrometry-based technique, called monoclonal immunoglobulin rapid accurate mass measurement (miRAMM), to extend the analytical range of M-protein detection in serum samples obtained from myeloma patients in stringent complete response (sCR) post-autologous stem cell transplant (ASCT). To aid the M-protein detection post ASCT, the accurate molecular mass of the M-protein light chain at diagnosis was determined in all patients (N=30) and used to positively identify clones in the sCR serum. Day 100 post-ASCT, sCR samples had miRAMM identifiable M-proteins in 81% of patients. Patients who had achieved only a partial remission (PR) pre-ASCT and those with IgG isotypes serum samples had the highest rate of M-protein detection by miRAMM. miRAMM positivity at single time points (day 100, 6 months or 12 months) did not correlate with progression-free survival (PFS). In contrast, sCR patients who did not decrease their miRAMM M-protein intensities in serial measurements had shorter PFS than those whose miRAMM intensities decreased (median 17.9 months vs 51.6 months; P<0.0017). miRAMM M-protein is a more sensitive blood-based test than traditional M-protein tests and could cost effectively aid in serially monitoring complete remission for continue response or biochemical relapse.
Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease
Authors: Claire E. Le Pichon, William J. Meilandt, Sara Dominguez, Hilda Solanoy, Han Lin, Hai Ngu, Alvin Gogineni, Arundhati Sengupta Ghosh, Zhiyu Jiang, Seung-Hye Lee, Janice Maloney, Vineela D. Gandham, Christine D. Pozniak, Bei Wang, Sebum Lee, Michael Siu, Snahel Patel, Zora Modrusan, Xingrong Liu, York Rudhard, Miriam Baca, Amy Gustafson, Josh Kaminker, Richard A. D. Carano, Eric J. Huang, Oded Foreman, Robby Weimer, Kimberly Scearce-Levie, Joseph W. Lewcock
Journal: Science Translational Medicine (2017)

Blocking dual leucine zipper kinase slows disease progression in animal models of ALS and Alzheimer’s disease.